Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Schering: The Next Wave Of Consolidation

Executive Summary

News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion
Advertisement

Related Content

Deals Of The Week: Idenix/Janssen, Genentech/Afraxis, Immunomedics/Algeta
Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says
Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says
Pipeline Integration Leaves Merck's Backbone As Cardiovascular, Infectious Disease
J&J Not Likely To Hold Its Peace At Merck/Schering Altar
A Goliath Grows: Pfizer To Buy Wyeth For $68 Billion
Merck Taking Aggressive Approach To Cardiovascular Development
Merck Taking Aggressive Approach To Cardiovascular Development
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
Pfizer Backs Out Of Cardiovascular R&D

Topics

Advertisement
UsernamePublicRestriction

Register

PS050815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel